VREX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VREX is not a good buy right now for an impatient trader. Despite a constructive longer-term moving-average structure, momentum has turned down (bearish/expanding MACD histogram) and the pattern-based forecast points to continued near-term downside (-1.07% next day, -2.96% next week, -5.21% next month). With earnings on 2026-02-05 (after hours) and no proprietary buy signals today, the near-term risk/reward is unattractive—avoid/exit rather than buy at $14.03.
Trend/Momentum: The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been improving. However, momentum is weakening: MACD histogram is negative (-0.0207) and negatively expanding, which typically precedes further pullback. RSI: RSI_6 at ~56.97 is neutral—no oversold bounce signal. Levels: Pivot ~14.00 is essentially current price. Immediate resistance is R1 ~14.42 then R2 ~14.67; support is S1 ~13.59 then S2 ~13.33. With fading momentum, a test of S1 is plausible before any sustainable push toward R1.
Intellectia Proprietary Trading Signals
Options market is heavily call-skewed (bullish sentiment).
Moving-average stack remains bullish (supportive longer-term technical backdrop).
2025/Q4 revenue growth (+11.28% YoY) and higher gross margin (+4.20% YoY) indicate improving top-line/mix.
Momentum deterioration: MACD histogram is negative and expanding, increasing near-term pullback risk.
Pattern-based outlook is bearish across 1D/1W/1M horizons.
Profitability slump in 2025/Q4: Net income and EPS down sharply YoY (suggesting earnings quality/one-offs or cost pressure).
Earnings catalyst ahead (2026-02-05 after hours) can amplify downside if results/guidance disappoint, especially with elevated implied volatility.
No supportive near-term news flow and no proprietary buy signals today.
Latest quarter: 2025/Q4. Revenue rose to $228.9M (+11.28% YoY) and gross margin improved to 33.99% (+4.20% YoY), which is constructive on operations. However, net income fell to $12.2M (-124.40% YoY) and EPS to $0.29 (-123.77% YoY), indicating a significant profitability deterioration versus last year (potentially driven by non-recurring items, higher costs, or below-the-line impacts). The mixed picture (growth up, earnings down) reduces confidence in near-term upside without a clearer earnings rebound.
No analyst rating/price-target change data was provided, so a recent trend cannot be confirmed from the dataset. With limited Wall Street signal visibility here, the tangible pros are improving revenue and gross margin; the key cons are the sharp YoY decline in net income/EPS and weakening technical momentum into the next earnings event. Politician/congress activity: no recent congress trading data available; hedge funds/insiders show neutral recent trends.
